Insider Transactions in Q1 2021 at Intra Cellular Therapies, Inc. (ITCI)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
208
+2.45%
|
$6,864
$33.93 P/Share
|
|
Mar 31
2021
|
Christopher D Alafi Director |
BUY
Grant, award, or other acquisition
|
Direct |
464
+0.13%
|
$15,312
$33.93 P/Share
|
|
Mar 31
2021
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
464
+0.74%
|
$15,312
$33.93 P/Share
|
|
Mar 31
2021
|
Richard A Lerner Director |
BUY
Grant, award, or other acquisition
|
Indirect |
442
+0.46%
|
$14,586
$33.93 P/Share
|
|
Mar 02
2021
|
Joel S Marcus |
SELL
Open market or private sale
|
Indirect |
15,250
-17.42%
|
$518,500
$34.93 P/Share
|
|
Mar 02
2021
|
Joel S Marcus |
BUY
Exercise of conversion of derivative security
|
Indirect |
20,000
+18.6%
|
$520,000
$26.58 P/Share
|
|
Feb 19
2021
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
27,847
-1.2%
|
$1,086,033
$39.09 P/Share
|
|
Feb 19
2021
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
11,139
-95.06%
|
$434,421
$39.09 P/Share
|
|
Feb 19
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
10,442
-94.25%
|
$407,238
$39.09 P/Share
|
|
Feb 19
2021
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,184
-5.19%
|
$202,176
$39.08 P/Share
|
|
Feb 19
2021
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,734
-5.33%
|
$106,626
$39.07 P/Share
|
|
Feb 18
2021
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,847
+2.34%
|
-
|
|
Feb 18
2021
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
11,139
+50.0%
|
-
|
|
Feb 18
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,442
+50.0%
|
-
|
|
Feb 18
2021
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,139
+18.06%
|
-
|
|
Feb 18
2021
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,354
+24.43%
|
-
|
|
Jan 11
2021
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
41,896
-1.79%
|
$1,298,776
$31.85 P/Share
|
|
Jan 11
2021
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
19,638
-95.07%
|
$608,778
$31.86 P/Share
|
|
Jan 11
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
19,638
-93.95%
|
$608,778
$31.86 P/Share
|
|
Jan 11
2021
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
9,684
-19.74%
|
$309,888
$32.02 P/Share
|
|
Jan 11
2021
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,367
-10.05%
|
$135,377
$31.87 P/Share
|
|
Jan 08
2021
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
41,896
+3.44%
|
-
|
|
Jan 08
2021
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
19,638
+50.0%
|
-
|
|
Jan 08
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,638
+50.0%
|
-
|
|
Jan 08
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Bona fide gift
|
Direct |
350
-100.0%
|
-
|
|
Jan 08
2021
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,948
+29.92%
|
-
|
|
Jan 08
2021
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,092
+37.47%
|
-
|
|
Jan 04
2021
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
48,341
-1.04%
|
$1,498,571
$31.17 P/Share
|
|
Jan 04
2021
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
16,160
-90.18%
|
$500,960
$31.17 P/Share
|
|
Jan 04
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
15,810
-84.25%
|
$490,110
$31.17 P/Share
|
|
Jan 03
2021
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,341
+2.82%
|
-
|
|
Jan 03
2021
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
16,160
+50.0%
|
-
|
|
Jan 03
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,160
+50.0%
|
-
|